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Human serum albumin (HSA) participates in heme scavenging;
in turn, heme endows HSA with myoglobin-like reactivity and
spectroscopicproperties.Here, the allosteric effect of ibuprofenon
peroxynitrite isomerization to NO3 catalyzed by ferric human
serum heme-albumin (HSA-heme-Fe(III)) is reported. Data were
obtained at 22.0 °C. HSA-heme-Fe(III) catalyzes peroxynitrite
isomerization in the absence andpresenceofCO2; the valuesof the
second order catalytic rate constant (kon) are 4.1 105 and 4.5
105 M1 s1, respectively. Moreover, HSA-heme-Fe(III) prevents
peroxynitrite-mediated nitration of free added L-tyrosine. The pH
dependence of kon (pKa  6.9) suggests that peroxynitrous acid
reacts preferentially with the heme-Fe(III) atom, in the absence
and presence of CO2. TheHSA-heme-Fe(III)-catalyzed isomeriza-
tionof peroxynitrite hasbeenascribed to the reactivepentacoordi-
natedheme-Fe(III) atom. In the absence andpresence ofCO2, ibu-
profen impairs dose-dependently peroxynitrite isomerization by
HSA-heme-Fe(III) and facilitates the nitration of free added L-ty-
rosine; the value of the dissociation equilibrium constant for ibu-
profen binding to HSA-heme-Fe(III) (L) ranges between 7.7 
104 and9.7104M.Underconditionswhere [ibuprofen] isL,
the kinetics of HSA-heme-Fe(III)-catalyzed isomerization of per-
oxynitrite is superimposable to that obtained in the absence of
HSA-heme-Fe(III) or in the presence of non-catalytic HSA-heme-
Fe(III)-cyanide complex andHSA. Ibuprofenbinding impairs allo-
stericallyperoxynitrite isomerizationbyHSA-heme-Fe(III), induc-
ing the hexacoordination of the heme-Fe(III) atom. These results
represent the first evidence for peroxynitrite isomerization by
HSA-heme-Fe(III), highlighting the allostericmodulationofHSA-
heme-Fe(III) reactivity by heterotropic interaction(s), and outlin-
ing the role of drugs in modulating HSA functions. The present
results could be relevant for the drug-dependent protective role of
HSA-heme-Fe(III) in vivo.
Human serum albumin (HSA),3 the most abundant protein in
plasma (reaching a blood concentration of about 7.0 104 M), is
characterized by an extraordinary ligandbinding capacity, provid-
ing a depot and carrier for many compounds. HSA affects the
pharmacokinetics ofmany drugs; holds some ligands in a strained
orientation, providing their metabolic modification; renders
potential toxins harmless, transporting them to disposal sites;
accounts for most of the antioxidant capacity of human serum;
and displays (pseudo)enzymatic properties (1–14).
HSAisasinglenon-glycosylatedall--chainproteinconstituted
by 585 amino acids, containing three homologous domains
(labeled I, II, and III). Each domain is made up by two separate
helical subdomains (namedA and B), connected by random coils.
Terminal regions of sequential domains contribute to the forma-
tion of interdomain helices linking domain IB to IIA and domain
IIB to IIIA, respectively (Fig. 1) (2, 3, 5, 7, 11, 13–25).
The structural organization of HSA provides a variety of
ligand binding sites (Fig. 1). According to Sudlow’s nomencla-
ture, bulky heterocyclic anions bind preferentially to Sudlow’s
site I (located in subdomain IIA), whereas Sudlow’s site II
(located in subdomain IIIA) is preferred by aromatic carboxy-
lates with an extended conformation (Fig. 1).Warfarin and ibu-
profen are considered as stereotype ligands for Sudlow’s site I
and II, respectively (1–3, 5, 12, 14, 16, 20, 26–30).
HSA is able to bind seven equivalents of long-chain fatty
acids (FAs) atmultiple binding sites (labeled FA1–FA7 in Fig. 1)
with different affinity (24, 31). In particular, FA1 is located
within the IB subdomain, contacting the IB-IIA polypeptide
linker and the long IB-IIA transdomain helix; FA2 is located at
the interface between subdomains IA, IB, and IIA; FA3 and FA4
together contribute to Sudlow’s site II (i.e. the ibuprofen site in
subdomain IIIA); FA5 is located within subdomain IIIB with
the ligandpolar head oriented toward subdomain IIIA; FA6 is at
the interface between subdomains IIA and IIB; FA7 corre-
sponds to Sudlow’s site I (i.e. the warfarin binding site in sub-
domain IIA). FA2 and FA6 clefts appear to be the secondary
binding sites of ibuprofen (1, 3, 12, 14, 16, 18–20, 32–35).
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The FA1 binding site has been shown to be the primary
binding site for heme, bilirubin, and fusidic acid, an antibi-
otic that competitively displaces bilirubin from HSA (14, 21,
23). There is increasing evidence that FA1 has evolved to
selectively bind heme-Fe(III) with high affinity (Kd  1.0 
108 M) (21, 23–25, 36, 37). The tetrapyrrole ring is arranged in
a D-shaped cavity limited by Tyr138 and Tyr161 residues that pro-
vide – stacking interactions with the porphyrin and supply a
donor oxygen (from Tyr161) for the heme-Fe(III) atom. Heme-
Fe(III) is secured to HSA by the long IA-IB connecting loop (21,
23–25, 36–38). In turn, heme endowsHSAwithmyoglobin (Mb)-
like reactivity and spectroscopic properties (11, 21, 23, 28, 30,
36–55).
Both heme-Fe(III) binding to HSA and HSA-heme-Fe(II)
reactivity are modulated allosterically, such that HSA-heme
could be considered as a prototype monomeric allosteric
macromolecule (21, 23–25, 30, 36–38, 45, 48, 52, 56).
Indeed, the affinity of the heme-Fe(III) for HSA decreases by
about 1 order of magnitude upon drug (e.g. warfarin) bind-
ing; on the other hand, heme-Fe(III) binding to HSA
decreases the drug affinity by the same extent (57). Further,
heme-Fe(III) inhibits ligand binding to Sudlow’s site I by
stabilizing the basic state of HSA, whereas ligand association
to Sudlow’s site I impairs HSA-heme-Fe(III) formation by
stabilizing the neutral state of HSA (21, 23–25, 30, 36, 52,
56). Moreover, heme-Fe(III) modulates competitively and
allosterically FA binding to HSA, since myristate binding to
all FA sites competes with heme-Fe(III) binding to FA1 and
at the same time induces the neutral to basic transition, facil-
itating heme-Fe(III) binding (5, 13, 23, 25, 37). In addition,
abacavir and warfarin have been reported to modulate allo-
sterically peroxynitrite-mediated oxidation of ferrous
nitrosylated HSA (HSA-heme-Fe(II)-NO) (50) and NO dis-
sociation from HSA-heme-Fe(II)-NO (51).
Here, ibuprofen, the prototype ligand of Sudlow’s site II (1, 3,
26, 58), is reported to impair peroxynitrite4 isomerization to
NO3 by HSA-heme-Fe(III), in the absence and presence of
CO2. In the absence of ibuprofen, the pentacoordinated HSA-
heme-Fe(III) form catalyzes peroxynitrite isomerization to
NO3, preventing the nitration of free added L-tyrosine. In con-
trast, ibuprofen induces hexacoordination of the heme-Fe(III)
atom of HSA-heme-Fe(III), impairing allosterically peroxyni-
trite isomerization by HSA-heme-Fe(III) and allowing the
nitration of free added L-tyrosine. These results represent the
first evidence for a drug-dependent peroxynitrite scavenging by
HSA-heme-Fe(III), a condition possibly occurring in patients
with various hemolytic diseases (59).
EXPERIMENTAL PROCEDURES
Materials
Hemin (Fe(III)-protoporphyrin IX) chloride was purchased
from Sigma. The heme stock solution (5.0 103 M) was pre-
pared by dissolving heme-Fe(III) in 1.0  102 M NaOH (60).
The heme-Fe(III) concentration was determined spectropho-
tometrically at 535 nm, after converting heme-Fe(III) to the
heme-Fe(III)-bisimidazolate derivative by adding 1.0 M imidaz-
ole, in SDS micelles (535 nm 14.5 103 M1 cm1) (61).
HSA (96%, essentially fatty acid-free) was obtained from
Sigma. To remove hydrophobic ligands, HSA was dissolved in
water, acidified to pH 3.5 with acetic acid, and treated for 2 hwith
activatedcharcoalat roomtemperature.Aftercharcoal removalby
centrifugation, the pHwas brought to 7.0 with aqueous ammonia
(62).TheHSAconcentrationwasdetermined spectrophotometri-
cally at 280 nm (280 nm 38.2 103 M1 cm1) (60). The HSA
stock solution (2.0 104 M) was prepared by diluting the hydro-
phobic ligand-free HSA solution with the 2.0  102 M sodium
phosphate buffer, at pH7.2. TheHSA-heme-Fe(III) stock solution
(2.0 104 M) was prepared by adding a 0.9-fold molar defect of
the heme-Fe(III) stock solution to theHSA solution (2.0 102 M
sodiumphosphate buffer, pH7.2) (30, 37, 42, 44, 50, 54, 55, 60, 63).
The HSA and HSA-heme(III) stock solutions were diluted in the
2.0  101 M sodium phosphate buffer at the desired pH value
(rangingbetween6.2and8.1) andconcentration (rangingbetween
1.0 105 and 1.0 104 M).
Peroxynitrite was synthesized from KO2 and NO and from
HNO2 and H2O2 and stored in small aliquots at 80.0 °C (64,
65). The peroxynitrite stock solution (2.0 103 M)was diluted
immediately before use with degassed 5.0  102 M NaOH to
reach the desired concentration (50, 66–69).Nitrate andnitrite
contaminations were in the range of 0–7% and 8–19% of the
peroxynitrite concentration, respectively (see “Methods”). The
concentration of peroxynitrite was determined spectrophoto-
metrically prior to each experiment by measuring the absorb-
ance at 302 nm (302 nm 1.705 103 M1 cm1) (64, 65).
Experiments in the presence of CO2, between pH 6.2 and 8.1,
were carried out by adding to the protein solutions the required
amount of a 5.0 101 MNaHCO3 solution. After the addition
4 The recommended IUPAC nomenclature for peroxynitrite is oxoperoxoni-
trate(1-), and the recommended nomenclature for peroxynitrous acid is
hydrogen oxoperoxonitrate. The term “peroxynitrite” is used here to refer
generically to both ONOO and its conjugate acid ONOOH (67, 70, 72).
FIGURE 1. HSA structure. The six subdomains of HSA are colored as fol-
lows. Blue, subdomain IA; cyan, subdomain IB; dark green, subdomain IIA;
light green, subdomain IIB; orange, subdomain IIIA; red, subdomain IIIB.
The heme (red) fits the primary cleft in subdomain IB, corresponding to
FA1. Sudlow’s site I (in subdomain IIA, corresponding to FA7) is occupied
by warfarin (purple). Sudlow’s site II (in subdomain IIIA, corresponding to
FA3-FA4) and FA6 (in subdomain IIB) are occupied by ibuprofen
(magenta). Sites FA2 (at the I-IIA interface) and FA5 (in subdomain IIIB) are
occupied by myristate (yellow). Atomic coordinates were taken from Pro-
tein Data Bank entries 1O9X (23), 1H9Z (20), and 2BXG (12).
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of bicarbonate, the protein solutions were allowed to equili-
brate for at least 5 min. For the experiments carried out in the
absence of CO2, all solutions were thoroughly degassed and
kept under nitrogen or helium (50, 66–69).
Experiments in the presence of cyanide at pH 7.2 were car-
ried out by adding 2.0 101 M cyanide to the HSA-heme(III)
and peroxynitrite/ibuprofen/L-tyrosine solutions, in the
absence and presence of CO2. This cyanide concentration
allowed to obtainmore than 90% of HSA-heme-Fe(III)-cyanide
complex (HSA-heme-Fe(III)-CN) (43, 52).
Ibuprofen was obtained from Sigma. The ibuprofen stock solu-
tion (1.0 102 M) was prepared by dissolving the drug in 2.0
102 M phosphate buffer at pH 7.2 (30). The final ibuprofen con-
centration ranged between 5.0 105 and 1.0 102 M.
L-Tyrosine and nitro-L-tyrosine were obtained from Sigma.
L-Tyrosine and nitro-L-tyrosine were dissolved in 1.0 101 M
phosphate buffer, at pH 7.2; the final L-tyrosine concentration
was 1.0 104 M (67, 70).
All of the other chemicals were obtained from Sigma and
Merck. All products were of analytical or reagent grade and
were used without further purification.
Methods
The kinetics of peroxynitrite isomerization in the absence and
presence of HSA-heme-Fe(III), HSA-heme-Fe(III)-CN, HSA,
CO2, ibuprofen, and L-tyrosinewas recordedwith theSMF-20and
SMF-400 rapid mixing stopped-flow apparatus (Bio-Logic SAS,
Claix, France). The light path of the observation cuvette was 10
mm, and the dead timewas 1.4ms. The kinetics wasmonitored at
302 nm, the characteristic absorbance maximum of peroxynitrite
(64, 65). Kinetic datawere obtained in the absence andpresence of
CO2 (final concentration, 1.2 103 M) and ibuprofen (final con-
centration, 5.0 105 to 1.0 102 M) by rapid mixing the pro-
tein solution (final concentration, 5.0106 to5.0105M)or the
buffersolution(1.0101Mphosphatebuffer)withtheperoxynitrite
solution(finalconcentration,2.5105 to2.5104M).Thekinet-
icswasobtainedat 22.0 °CandbetweenpH6.2 and8.1 (1.0101
Mphosphate buffer); the pHwas alwaysmeasured at the endof the
reaction. No gaseous phase was present.
The kinetics of peroxynitrite isomerization in the absence and
presence of HSA-heme-Fe(III) was analyzed in the framework of
the minimum reaction Schemes 1 and 2, respectively (67, 70),
HOONO O¡
k0
NO3
 H
SCHEME 1
HSA-heme-Fe(III)  HOONOO¡
kon
HSA-heme-Fe(III)-OONOO¡
fast
HSA-heme-Fe(III)  NO3
 H
SCHEME 2
Values of the first-order rate constant for peroxynitrite
isomerization in the presence of HSA-heme-Fe(III)-CN, HSA,
and 1.0 101 M phosphate buffer (i.e. k0 or k0i in the absence
and presence of ibuprofen, respectively) and of the pseudo-
first-order rate constant for HSA-heme-Fe(III)-mediated
peroxynitrite isomerization (i.e. kobs or kobsi in the absence
and presence of ibuprofen, respectively) have been deter-
mined, in the absence and presence of CO2, between pH 6.2
and 8.1 at 22.0 °C, from the analysis of the time-dependent
absorbance decrease at 302 nm, according to Equation 1 (67,
69–74),
peroxynitritet peroxynitritei e
k t (Eq. 1)
where k is k0 or kobs in the absence of ibuprofen and k0i or kobsi in
the presence of ibuprofen.
Values of the second-order rate constant for HSA-heme-
Fe(III)-mediated peroxynitrite isomerization (i.e. kon or koni in
the absence and presence of ibuprofen, respectively) have been
determined, in the absence and presence of CO2, between pH
6.2 and 8.1 at 22.0 °C, from the linear dependence of kobs or kobsi
on the HSA-heme-Fe(III) concentration according to Equa-
tions 2 and 3 (67, 70, 71, 73),
kobs kon [HSA-heme-Fe(III)] k0 (Eq. 2)
kobs
i  kon
i  HSA-heme-Fe(III) k0
i (Eq. 3)
The pH dependence of k0 and kon for peroxynitrite isomeriza-
tion in the absence and presence ofHSA-heme-Fe(III) allows us
to obtain, in the absence of ibuprofen and both in the absence
and presence of CO2, at 22.0 °C, the values of pKa, klim(top) and
klim(bottom) (67, 70–72) according to Equation 4,
k  k lim(top) 10
pH/10pH 10pKa (Eq. 4)
where k is k0 or kon, and klim(top) represents the top asymptotic
value of k under conditions where pH		 pKa, and Equation 5,
k  k lim(top) klim(bottom) 10
pH/10pH 10pKa
 klim(bottom) (Eq. 5)
where k is k0 or kon, and klim(top) and klim(bottom) represent the
asymptotic values of k under conditions where pH 		 pKa or
pH pKa, respectively.
The value of the dissociation equilibrium constant for ibu-
profen binding toHSA-heme-Fe(III) (L) was determined, at pH
7.2, from the dependence of koni on the ibuprofen concentration
(ranging between 5.0  105 and 1.0  102 M). The effect of
ibuprofen concentration on koni was analyzed according to
Equation 6 (30, 51, 71),
kon
i  kon(top)
i  kon(top)
i  ibuprofen/L ibuprofen
(Eq. 6)
where kon(top)i represents the asymptotic value of koni under con-
ditions where [ibuprofen] 0 (i.e. kon(top)i  kon).
NO2 and NO3 analysis was carried out spectrophotometri-
cally at 543 nmby using theGriess reagent andVCl3 to catalyze
the conversion ofNO3 toNO2, as described previously (70, 75,
76). Calibration curves were obtained bymeasuring 4–8 stand-
ard sodiumnitrite and sodiumnitrate solutions in 1.0 101 M
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phosphate buffer, pH 7.2, and 22.0 °C. The samples were pre-
pared by mixing 500 	l of a HSA-heme-Fe(III) solution (initial
concentration, 1.0 104 M in 2.0 101 M phosphate buffer,
pH 7.2) with 500 	l of a peroxynitrite solution (initial concen-
tration, 4.0 104 M in 1.0 102 MNaOH)while vortexing, at
22.0 °C, in the absence and presence of CO2 (1.2 103 M) and
ibuprofen (2.5  103 M). The reaction mixture was analyzed
within 
10 min. At least four separate experiments were car-
ried out.
The reaction of peroxynitrite with free L-tyrosine was carried
out at pH 7.2 and 22.0 °C by adding 0.2 ml of an alkaline (1.0
102 MNaOH) ice-cooled solution of peroxynitrite (2.0 103
M) to 1.8 ml of a buffered (1.0  101 M phosphate buffer)
solution of L-tyrosine (final concentration, 1.0 104 M) in the
absence and presence of HSA-heme-Fe(III), HSA-heme-
Fe(III)-CN, HSA (final concentration, 5.0 106 to 5.0 105
M), ibuprofen (final concentration, 2.0 104 to 5.0 103 M),
and CO2 (final concentration, 1.2  103 M), as previously
reported (67, 70).
The amount of nitro-L-tyrosine was determined by HPLC, as
reported previously (67, 70). The chromatographic system con-
sisted of a Waters 600 pump and a Waters autosampler 717
PLUS equipped with a spectrophotometric UV-visible dual
wavelength system,Waters 2487 (Waters,Milford,MA).Nitro-
L-tyrosine separation was performed at 24.0 °C on the Grace
Vydac 218TP54 Protein&Peptide C18 column (250 4.6 mm)
equipped with a Grace Vydac guard cartridge filled with the
same packing material (Grace Vydac, Columbia, MD). The
mobile phase was composed of solutions A (0.07% trifluoroace-
tic acid in H2O) and B (0.07% trifluoroacetic acid in acetoni-
trile). Both solutions were degassed by purging with helium.
The injection volume was 20 	l. Nitro-L-tyrosine was eluted
(7.48 0.05 min after injection) by keeping the amount of sol-
vent B constant (5%) in the first 2 min and then by using an
increasing linear gradient of B from 5 to 10% between 2 and 10
min and from 10 to 80% between 10 and 15 min. Nitro-L-tyro-
sinewas detected at 220, 280, 350, and 400 nm.Nitro-L-tyrosine
was quantified by measuring a calibration curve of seven nitro-
L-tyrosine standard solutions. The Millenium software
(Waters) was used to pilot theHPLC instrument and to process
the data (i.e. area integration, calculation, and plotting of chro-
matograms) throughout the method validation and sample
analysis.
The value of the dissociation equilibrium constant for ibu-
profen binding toHSA-heme-Fe(III) (L) was determined, at pH
7.2 and 22.0 °C, from the dependence of the relative yield of
nitro-L-tyrosine formed from the reaction of peroxynitrite with
free L-tyrosine (Y) on the drug concentration ([ibuprofen],
ranging between 2.0 104 and 5.0 103 M). The effect of the
ibuprofen concentration on Ywas analyzed according to Equa-
tion 7 (30, 51, 71),
Y  100  R  ibuprofen/L ibuprofen R
(Eq. 7)
where R corresponds to Y in the absence of ibuprofen.
The value of the dissociation equilibrium constant for ibu-
profen binding to HSA-heme-Fe(III) (L) was also obtained
spectrophotometrically at 404 nm (by a Cary 50 Bio spectro-
photometer; Varian Inc., Palo Alto, CA), using an optical cell
with 1.0-cm path length, at 22.0 °C. Small aliquots of the 1.2
102 M heme-Fe(III) and 1.0  103 M HSA solutions were
diluted in the optical cell in 1.0 101 M phosphate buffer, 10%
DMSO, pH 7.0, to a final HSA-heme-Fe(III) concentration of
1.0 105 M. Then small aliquots of the 1.0 103 M ibuprofen
solution were added to the HSA-heme-Fe(III) solution, and the
absorbance spectra were recorded after incubation for a few
minutes after each addition. Ibuprofen binding to HSA-heme-
Fe(III) was analyzed by plotting the Soret band absorbance
change (A) as a function of the ibuprofen concentration. Data
were analyzed according to Equation 8 (30, 51, 71),
A  Amax ibuprofen/L ibuprofen (Eq. 8)
where Amax is the absorbance change at saturating ibuprofen
concentration.
Kinetic and thermodynamic data were analyzed using the
MatLab program (The Math Works Inc., Natick, MA). The
results are given as mean values of at least four experiments
S.D.
RESULTS
HSA-Heme(III) Catalyzes Peroxynitrite Isomerization—The
kinetics of peroxynitrite isomerization, both in the absence and
presence of HSA-heme-Fe(III), HSA-heme-Fe(III)-CN, HSA,
and CO2, was recorded by a single-wavelength stopped-flow
apparatus. Under all of the experimental conditions, a decrease
of the absorbance at 302 nm was observed, as previously
reported (67, 69, 70, 72–74). The kinetics of peroxynitrite
isomerization was fitted to a single-exponential decay for more
than 97% of its course (supplemental Fig. S1). According to the
literature (67, 70), this indicates that no intermediate species
(e.g. HSA-heme-Fe(III)-OONO; see Scheme 2) accumulate(s)
in the course of peroxynitrite isomerization. In particular, the
formation of the transient HSA-heme-Fe(III)-OONO species
represents the rate-limiting step in catalysis, the conversion of
the HSA-heme-Fe(III)-OONO complex to HSA-heme-Fe(III)
and NO3 being faster by at least 1 order of magnitude.
In the absence of CO2, the observed rate constant for HSA-
heme-Fe(III)-catalyzed isomerization of peroxynitrite (kobs)
increases linearly with the HSA-heme-Fe(III) concentration
over thewhole pH range explored (Fig. 2A). The analysis of data
reported in Fig. 2A, according to Equation 2, allowed the deter-
mination of values of the first-order rate constant for peroxyni-
trite isomerization in the absence ofHSA-heme-Fe(III) (k0; cor-
responding to the y intercept of the linear plots) and of the
second-order rate constant for peroxynitrite isomerization by
HSA-heme-Fe(III) (kon; corresponding to the slope of the linear
plots). Values of k0 for peroxynitrite isomerization in the
absence of HSA-heme-Fe(III) (Table 1) are in good agreement
with those obtained in the presence of HSA-heme-Fe(III)-CN
andHSA (Fig. 2B) and reported in the literature (67, 70, 72, 74).
Because of the physiological relevance attributed to the reac-
tion between CO2 and peroxynitrite (79, 74, 77–79), the effect
of the physiological concentration of CO2 on peroxynitrite
isomerization by HSA-heme-Fe(III), HSA-heme-Fe(III)-CN,
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and HSA has been investigated. As shown in Fig. 2C, HSA-
heme-Fe(III) catalyzes the isomerization of peroxynitrite in a
concentration-dependent linear fashion. The analysis of data
reported in Fig. 2C, according to Equation 2, allowed the deter-
mination of values of the first-order rate constant for peroxyni-
trite isomerization in the absence ofHSA-heme-Fe(III) (k0; cor-
responding to the y intercept of the linear plots) and of the
second-order rate constant for peroxynitrite isomerization by
HSA-heme-Fe(III) (kon; corresponding to the slope of the linear
plots). In the presence of CO2, val-
ues of k0 for peroxynitrite isomer-
ization in the absence of HSA-
heme-Fe(III) (Table 1) are in good
agreement with those obtained in
the presence of HSA-heme-
Fe(III)-CN and HSA (Fig. 2D) and
reported in the literature (67, 70,
74).
Values of kon for HSA-heme-
Fe(III)-catalyzed isomerization of
peroxynitrite are essentially unaf-
fected by CO2 (Table 1). In contrast,
values of k0 for peroxynitrite
isomerization obtained in the pres-
ence of HSA-heme-Fe(III)-CN,
HSA, and CO2 are 10–100 times
higher than those obtained in the
absence of CO2 (Table 1). The lack
of a CO2-linked effect on peroxyni-
trite isomerization by HSA-heme-
Fe(III) is probably related to the fact
that peroxynitrite reacts faster with
HSA-heme-Fe(III) (kon 4.1 105
and 4.5  105 M1 s1, in the
absence and presence of CO2,
respectively) (Table 1) than with
CO2 (the second-order rate con-
stant being 3 104 M1 s1) (74, 79).
To confirm the catalytic effect of HSA-heme-Fe(III) on per-
oxynitrite isomerization, the dependence of kobs and k0 on the
peroxynitrite concentrationwas determined in the absence and
presence of HSA-heme-Fe(III), HSA-heme-Fe(III)-CN, HSA,
and CO2 concentration, at pH 6.2 (data not shown), 7.2 (Fig. 3),
and 8.1 (data not shown). Under all the experimental condi-
tions, values of kobs and k0 for peroxynitrite isomerization
slightly decrease upon increasing peroxynitrite concentration.
In contrast, the amplitude of the kinetics increases as a function
of the peroxynitrite concentration (data not shown). The
decrease of kobs and k0 values upon increasing peroxynitrite
concentration at fixed HSA-heme-Fe(III) concentration in the
absence and presence of CO2 (Fig. 3) is reminiscent of what has
been reported for peroxynitrite isomerization by human Hb-
Fe(III) and horse heart Mb-Fe(III) (70). This behavior has been
proposed to reflect the occurrence of the peroxynitrite/peroxy-
nitrous acid adduct at [peroxynitrite]  5.0  105 M, around
neutrality (70). Accordingly, the decrease of kobs and k0 values
upon increasing the peroxynitrite concentration may reflect
either the slow HSA-heme-Fe(III)-mediated decomposition of
the peroxynitrite/peroxynitrous acid adduct or the slow disso-
ciation of the peroxynitrite/peroxynitrous acid adduct preced-
ing HSA-heme-Fe(III)-catalyzed peroxynitrite isomerization.
To highlight the role of the heme-Fe(III) atom to catalyze
peroxynitrite isomerization, the effect of HSA-heme-
Fe(III)-CNandHSAconcentration on the isomerization of per-
oxynitrite was investigated in the absence and presence of CO2.
As shown in Fig. 2,B andD, HSA-heme-Fe(III)-CNandHSAdo
not affect the peroxynitrite isomerization kinetics. Therefore,
FIGURE 2. Dependence of the (pseudo-)first-order rate constant for peroxynitrite isomerization on the
HSA-heme-Fe(III) (kobs;AandC), HSA-heme-Fe(III)-CN (k0;BandD), andHSA (k0;BandD) concentration,
in theabsence (AandB) andpresence (CandD) ofCO2at22.0 °C.Theperoxynitrite concentrationwas2.5
104 M. The CO2 concentration was 1.2 10
3
M. The continuous lines in A and Cwere calculated according to
Equation 2with values of k0 and kon given in Table 1.Wherenot shown, the S.D. value is smaller than the symbol
in A and C. For clarity, the S.D. is shown for two k0 values in B and D.
TABLE 1
pH dependence of k0 and kon values for peroxynitrite isomerization
in the absence and presence of HSA-heme-Fe(III) and CO2, at 22.0 °C
1.0 101 M sodium phosphate buffer was used. The CO2 concentration was 1.2
103 M. In italic type are shown the values of k0 for peroxynitrite isomerization
obtained in the absence of HSA-heme-Fe(III). In normal type are shown values of k0
for HSA-heme-Fe(III)-catalyzed peroxynitrite isomerization.
pH k0 konWithout CO2 With CO2 Without CO2 With CO2
s1 M1 s1
6.2 0.67 4.1
0.69 3.9 1.1 106 1.3 106
6.4 0.64 6.2
0.62 6.1 9.8 105 9.6 105
6.7 0.43 8.9
0.48 9.1 7.9 105 8.1 105
6.9 0.35 11.9
0.38 12.3 6.7 105 6.4 105
7.2 0.28 17.4
0.26 17.8 4.1 105 4.5 105
7.5 0.11 25.3
0.14 24.9 2.3 105 2.2 105
7.8 0.086 32.9
0.078 33.5 1.3 105 1.5 105
8.1 0.046 43.7
0.041 42.8 6.8 104 8.2 104
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the acceleration of the peroxynitrite isomerization rate by
HSA-heme-Fe(III) could be due to the reaction of peroxynitrite
with the heme-Fe(III) atom, as reported for human Hb-Fe(III)
and horse heart Mb-Fe(III) (70).
The pH dependence of k0 and kon for peroxynitrite isomer-
ization, in the absence and presence of HSA-heme-Fe(III) and
CO2, was examined to identify tentatively the species that pref-
erentially react(s) with HSA-heme-Fe(III). Values of k0 and kon
shown in Fig. 4 were derived from data reported in Fig. 2,A and
C, and are listed in Table 1. Values of k0 for peroxynitrite
isomerization in the absence of HSA-heme-Fe(III) and CO2
decrease upon increasing pH from 6.2 to 8.1 (Fig. 4A). In con-
trast, values of k0 for peroxynitrite isomerization in the absence
of HSA-heme-Fe(III) but in the presence of CO2 increase upon
raising the pH from 6.2 to 8.1 (Fig. 4B). In the absence and
presence of CO2, the pH dependence of kon values for HSA-
heme-Fe(III)-mediated isomerization of peroxynitrite (Fig. 4C)
is closely similar to that of k0 for peroxynitrite isomerization in
the absence of HSA-heme-Fe(III) and CO2 (Fig. 4A). The anal-
ysis of data reported in Fig. 4, according to Equations 4 and 5,
allowed the estimation of pKa values for the pH dependence of
k0 and kon values for peroxynitrite isomerization in the absence
and presence of HSA-heme-Fe(III) and CO2.
The pH dependence of k0 for peroxynitrite isomerization in
the absence of both HSA-heme-Fe(III) and CO2 (pKa  6.8)
(Fig. 4A) and of kon for peroxynitrite isomerization by HSA-
heme-Fe(III) in the absence and presence of CO2 (pKa  6.9)
(Fig. 4C) is similar. The pKa value (6.8) for the pH dependence
of k0 for peroxynitrite isomerization in the absence of both
HSA-heme-Fe(III) and CO2 here determined is in excellent
agreement with pKa values reported in the literature (74). In
contrast, the pH dependence of k0
for peroxynitrite isomerization in
the absence of HSA-heme-Fe(III)
but in the presence of CO2 (pKa 
7.6) (Fig. 4B) is different from that of
k0 for peroxynitrite isomerization in
the absence of both HSA-heme-
Fe(III) and CO2 (pKa  6.8) (Fig.
4A) and of kon for peroxynitrite
isomerization by HSA-heme-Fe(III)
in the absence and presence of CO2
(pKa 6.9) (Fig. 4C).
According to the literature (67,
70), the close similarity of the pH
dependence of k0 for peroxynitrite
isomerization in the absence of both
HSA-heme-Fe(III) and CO2 (pKa
6.8) (Fig. 4A) and of kon for per-
oxynitrite isomerization by HSA-
heme-Fe(III) in the absence and
presence of CO2 (pKa  6.9) (Fig.
4C) suggests that in all cases,
HOONO is the species that reacts
preferentially with the heme-Fe(III)
atom. Conversely, the different pKa
value observed for peroxynitrite
isomerization in the presence of
CO2 and in the absence of HSA-heme-Fe(III) (pKa 7.6) (Fig.
4B) could indicate that the species undergoing the isomeriza-
tion is a transient highly reactive intermediate(s) formed by the
reaction of peroxynitrite with CO2. Since peroxynitrite has
been reported to react with CO2, leading to the formation of an
adduct whose composition is believed to be ONOOC(O)O
(named 1-carboxylato-2-nitrosodioxidane) (74, 79), this might
be the transient species that then converts to NO3 and CO2
either directly or by transient formation of trioxocarbonate(1-)
(CO3. ) and NO2. On the other hand, the similar pKa values for
peroxynitrite isomerization by HSA-heme-Fe(III), both in the
absence and in the presence of CO2 (pKa 6.9), indicates that
peroxynitrite reacts with HSA-heme-Fe(III) as HOONO.
Ibuprofen Impairs HSA-Heme-Fe(III)-mediated Isomeriza-
tion of Peroxynitrite—In the absence and presence of CO2, ibu-
profen impairs dose-dependently HSA-heme-Fe(III)-mediated
isomerization of peroxynitrite (Fig. 5). Mixing HSA-heme-
Fe(III) with peroxynitrite, in the presence of ibuprofen and in
the absence and presence of CO2, brings about a decrease of the
absorbance at 302 nm (supplemental Fig. S2, A and B). More-
over, the kinetics of peroxynitrite isomerization byHSA-heme-
Fe(III), in the presence of ibuprofen and in the absence and
presence of CO2, was fitted to a single-exponential decay for
more than 97% of its course (supplemental Fig. S2, A and B).
These findings agree with the results concerning peroxynitrite
isomerization in the absence of ibuprofen (see above and sup-
plemental Fig. S1).
The observed rate constant for HSA-heme-Fe(III)-catalyzed
isomerization of peroxynitrite (kobsi ) increases linearly with the
HSA-heme-Fe(III) concentration over the whole ibuprofen
concentration range explored, in the absence and presence of
FIGURE 3. Effect of peroxynitrite concentration on values of the (pseudo-)first-order rate constant for
peroxynitrite isomerization in the presence of HSA-heme-Fe(III) (kobs; A and C), HSA-heme-Fe(III)-CN
(kobs;BandD), HSA (kobs;BandD), and1.010
1Mphosphatebuffer (k0;BandD) in theabsence (Aand
B) or presence (C andD) of CO2, at pH 7.2 and 22.0 °C. The HSA-heme-Fe(III), HSA-heme-Fe(III)-CN, and HSA
concentrations were 5.0  106 M. The CO2 concentration was 1.2  10
3
M. For clarity, the S.D. value was
shown for prototypical kobs and k0 values in each panel.
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CO2. The analysis of data reported in Fig. 5,A and B, according
to Equation 3, allowed the determination of values of the first-
order rate constant for peroxynitrite isomerization in the
absence of HSA-heme-Fe(III) (k0i ; corresponding to the y inter-
cept of the linear plots) and of the second-order rate constant
for peroxynitrite isomerization by HSA-heme(III) (koni ; corre-
sponding to the slope of the linear plots) in the presence of
ibuprofen and in the absence and presence of CO2. As shown in
Table 2, CO2 does not affect koni values but alters k0i values.
The effect of ibuprofen concentration on koni values forHSA-
heme-Fe(III)-mediated isomerization of peroxynitrite is shown
in Fig. 5C. Values of k0i and koni shown in Fig. 5C were derived
from data reported in Fig. 5, A and B, and are listed in Table 2.
Values of k0i are unaffected by ibuprofen concentration
FIGURE 4. Effect of pH on the first-order rate constant for peroxynitrite
isomerization (k0) in the absence (A) and presence (B) of CO2 and on the
second-order rate constant for HSA-heme-Fe(III)-mediated peroxyni-
trite isomerization (kon) in the absence (left) and presence (right) of CO2
(C), at 22.0 °C. Values of k0 in A and B are the average of those obtained from
experiments of peroxynitrite isomerization in the absence and presence of
HSA-heme-Fe(III) (see Table 1). The peroxynitrite concentration was 2.5 
104 M. The CO2 concentrationwas 1.2 10
3
M. The continuous line in Awas
calculated according to Equation 4with pKa 6.8 and klim(top) 0.86 s
1. The
continuous line in B was calculated according to Equation 5 with pKa  7.6,
klim(top) 55.3 s
1, and klim(bottom) 3.1 s
1. Both continuous lines in C were
calculated according to Equation 4 with pKa  6.9 and klim(top)  1.4  10
6
M
1 s1. Where not shown, the S.D. value is smaller than the symbol.
FIGURE5.Effectof the ibuprofenconcentrationonthedependenceof the
pseudo-first-order rate constant for peroxynitrite isomerization (kobs
i )
on the HSA-heme-Fe(III) concentration, in the absence (A) and presence
(B) of CO2, at pH 7.2 and 22.0 °C. Data reported in panels A and B were
obtained at [ibuprofen] 0.0 M (a), 1.0 103 M (b), and 2.5 103 M (c). The
continuous lines in A and B were calculated according to Equation 3 with
values of kon
i and k0
i given in Table 2. Shown is the effect of the ibuprofen
concentration on the second-order rate constant for HSA-heme(III)-catalyzed
isomerizationofperoxynitrite (kon
i ) in the absence (left) andpresence (right) of
CO2 (C). Both continuous lines were calculated according to Equation 4 with
L 9.7 104 M and kon(top)
i  4.3 105 M1 s1. Where not shown, the S.D.
value is smaller than the symbol.
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(Table 2). In contrast, values of koni for HSA-heme(III)-cata-
lyzed isomerization of peroxynitrite decrease from 4.1  105
M1 s1 in the absence of ibuprofen to 3.5  104 M1 s1 at
[ibuprofen]  1.0  102 M in the absence of CO2 and from
4.5 105 M1 s1 in the absence of ibuprofen to 9.0 104 M1
s1 at [ibuprofen] 4.0 103 M in the presence ofCO2 (Table
2). The analysis of the dependence of koni for HSA-heme(III)-
catalyzed isomerization of peroxynitrite, according to Equation
4, allowed the determination of the CO2-independent value of
the dissociation equilibrium constant for ibuprofen binding to
HSA-heme-Fe(III) (L 9.7 104 M).
Analysis of the Nitrogen-containing Products of Peroxynitrate
Isomerization—According to the literature (70, 80), the spon-
taneous isomerization of peroxynitrite yielded 76  4% NO3
and 23  3% NO2. In the presence of HSA-heme-Fe(III), the
NO3 andNO2 yields increased (
90%) and decreased (
10%),
respectively, as reported for peroxynitrite isomerization cata-
lyzed by humanHb-Fe(III) andhorse heartMb-Fe(III) (70). The
same result has been observed in the presence of HSA-heme-
Fe(III) and/or CO2, according to the literature (70, 80). Last,
ibuprofen does not significantly affect theNO3 andNO2 yields
(supplemental Table S1).
Ibuprofen Impairs HSA-Heme-Fe(III)-based Protection of
Free L-Tyrosine against Peroxynitrite-mediated Nitration—To
investigate the protective role of HSA-heme-Fe(III) against
peroxynitrite-mediated nitration, the relative yield of nitro-L-
tyrosine formed by the reaction of peroxynitrite with free L-ty-
rosine in the presence of HSA-heme-Fe(III) was determined.
For this purpose, 0.2 ml of a peroxynitrite solution were mixed
with a free L-tyrosine solution, in the absence and presence of
HSA-heme-Fe(III), HSA-heme-Fe(III)-CN, HSA, ibuprofen,
and CO2, as previously reported (67, 70). Note that CO2 facili-
tates peroxynitrite-mediated nitration of L-tyrosine, redirect-
ing peroxynitrite specificity (69, 74, 79).
As shown in Fig. 6, HSA-heme-Fe(III) protects dose-depend-
ently free L-tyrosine against peroxynitrite-mediated nitration.
In contrast, L-tyrosine nitration is not prevented byHSA-heme-
Fe(III)-CN andHSA, and the relative nitro-L-tyrosine yield cor-
responds to that observed in the absence of HSA derivatives.
According to previous results (67, 70), HSA-heme-Fe(III) was
slightly less efficient at preventing peroxynitrite-mediated
nitration of free L-tyrosine in the presence than in the absence
of CO2.
The ability of ibuprofen to impair allosterically HSA-heme-
Fe(III)-mediated peroxynitrite isomerization prompted us to
investigate the role of this drug in modulating peroxynitrite-
based L-tyrosine nitration, in the absence and presence of CO2.
The relative yield of nitro-L-tyrosine increased upon increasing
the ibuprofen concentration, at fixed HSA-heme-Fe(III), per-
oxynitrite, L-tyrosine, andCO2 concentration (Fig. 7). The anal-
ysis of the data, according to Equation 7, allowed the determi-
nation of values of the dissociation equilibrium constant L in
the absence and presence of CO2 (8.7 104 and 8.4 104 M,
respectively).
Spectrophotometric Evidence for Ibuprofen Binding to
HSA-Heme-Fe(III)—To further support ibuprofen binding to
HSA-heme-Fe(III), the value of the dissociation equilibrium
constant for complex formation (L) has been determined spec-
trophotometrically (Fig. 8). The analysis of the data, according
to Equation 6, allowed the determination of the dissociation
equilibrium constant L (7.7 104 M). The value of L obtained
spectrophotometrically (7.7  104 M) (Fig. 8) is in excellent
TABLE 2
Effect of the ibuprofen concentration on k0
i and kon
i values for
HSA-heme-Fe(III)-mediated peroxynitrite isomerization in the
absence and presence of CO2, at pH 7.2 and 22.0 °C
Ibuprofen k0
i koni
Without CO2 With CO2 Without CO2 With CO2
M s1 M1 s1
0.0a 0.26a 17.8a 4.1 105 a 4.5 105 a
5.0 105 NDb 19.3 ND 4.1 105
1.0 104 0.23 ND 3.9 105 ND
2.0 104 0.28 18.1 3.5 105 3.6 105
4.0 104 0.25 17.6 2.9 105 3.2 105
8.0 104 0.22 ND 2.4 105 ND
1.0 103 0.24 18.4 2.2 105 2.0 105
1.6 103 ND 19.0 ND 1.7 105
2.0 103 0.26 ND 1.5 105 ND
2.5 103 0.25 18.4 1.1 105 1.2 105
4.0 103 ND 16.9 ND 9.0 104
5.0 103 0.27 ND 7.5 104 ND
1.0 102 0.22 ND 3.5 104 ND
a Under conditions where ibuprofen  0.0 M, k0i  k0, and koni  kon.
bND, not determined.
FIGURE 6. Effect of HSA-heme-Fe(III), HSA-heme-Fe(III)-CN, andHSA con-
centration on the relative yield of nitro-L-tyrosine formed from the reac-
tion of peroxynitrite with free L-tyrosine, at pH 7.2 and 22.0 °C, in the
absence (A) and presence (B) of CO2. The free L-tyrosine concentration was
1.0 104 M. The peroxynitrite and CO2 concentration was 2.0 10
4 and
1.2103M, respectively. Relative yield (%) (yieldwithaddedprotein/yield
with no protein) 100. Where not shown, the S.D. value is smaller than the
symbol.
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agreement with those obtained from the effect of ibuprofen
concentration on (i) HSA-heme-Fe(III)-catalyzed isomeriza-
tion of peroxynitrite in the absence and presence of CO2 (L 
9.7 104M) (Fig. 5C) and (ii) the relative nitro-L-tyrosine yield
in the absence and presence of CO2 (L 8.7 104 and 8.4
104 M, respectively) (Fig. 7). Note that the heme-Fe(III)-ibu-
profen complex, which could potentially interfere, only occurs
at an ibuprofen concentration of7.5 102 (38).
DISCUSSION
Ibuprofen, the prototype ligand of Sudlow’s site II (1, 3, 26,
58), modulates allosterically peroxynitrite isomerization by
HSA-heme-Fe(III) and therefore the peroxynitrite-mediated
nitration of free L-tyrosine, highlighting the role of heterotropic
ligands on the HSA reactivity (11, 13, 52, 81).
Peroxynitrite isomerization is facilitated by the HSA-
heme-Fe(III) species, whereas the HSA-heme-Fe(III)-CN
derivative and the heme-free HSA are both non-reactive,
clearly demonstrating that the efficiency of the isomeriza-
tion process mirrors the heme-Fe(III) reactivity. As already
reported for horse and sperm whale Mb and human Hb (67,
70), peroxynitrous acid appears to be the species that pref-
erentially reacts with HSA-heme-Fe(III). In addition, like
horse heart Mb, sperm whale Mb, and human Hb (67, 70),
HSA-heme-Fe(III) protects free L-tyrosine from peroxyni-
trite-mediated nitration.
Allosteric inhibition of the HSA-heme-Fe(III)-mediated
peroxynitrite isomerization by ibuprofen is related to drug-
dependent structural changes occurring at the FA1 site (i.e.
at the heme binding pocket). Indeed, UV-visible, resonance
Raman, and electron paramagnetic resonance spectrosco-
pies evidenced that the pentacoordinated heme-Fe(III) atom
of HSA-heme-Fe(III), observed in the absence of ibuprofen,
becomes hexacoordinated low spin upon ibuprofen binding
(38). On the basis of the crystal structure of HSA-heme-
Fe(III) (21), the His146 residue was suggested as the putative
ligand able to coordinate to the heme-Fe(III) atom in the
sixth position upon ibuprofen binding (38). In contrast, in
both ibuprofen-free pentacoordinated and ibuprofen-bound
hexacoordinated HSA-heme-Fe(III), the Tyr161 residue
coordinates to the heme-Fe(III) atom in the fifth position
(38). Therefore, the presence of a strong ligand (either the
His146 residue or the exogenous cyanide ligand) at the sixth
coordination position of the heme-Fe(III) atom inhibits per-
oxynitrite isomerization, thus rendering HSA-heme-Fe(III)
non-reactive.
The identity of the ibuprofen binding pocket(s) (among the
three possible ones, namely FA2, FA6, and Sudlow’s site II)
responsible for this allosteric effect is still unclear.
Structural and solution studies of ibuprofen binding to HSA
have shown that the ibuprofen primary binding site (i.e. Sud-
low’s site II formed by FA3 and FA4 clefts) does not appear to be
allosterically linked to the heme binding site (i.e. FA1) (30, 37,
38, 55), ruling out the possibility that Sudlow’s site II is respon-
sible for the effect of ibuprofen on peroxynitrite isomerization
by HSA-heme-Fe(III).
An additional candidate might be the ibuprofen secondary
site FA6, which modulates negatively heme-Fe(III) binding
to FA1 (12, 37) and the affinity of the secondary drug binding
cleft FA2 (34, 37, 38, 81). The FA6 site (located within
domain II at the interface between subdomains IIA and IIB)
FIGURE 7. Effect of ibuprofen concentration on the relative yield of nitro-
L-tyrosine formed fromthe reactionofperoxynitritewith free L-tyrosine,
at pH 7.2 and 22.0 °C, in the presence of HSA-heme-Fe(III) and in the
absence (A) and presence (B) of CO2. The continuous lines were calculated
according to Equation 7with the following parameters: L 8.7 104 M and
r 21.1% (A) and L 8.4 104 M and r 25.9% (B). The concentration of
HSA-heme-Fe(III), peroxynitrite, free L-tyrosine, andCO2was2.510
5, 2.0
103, 1.0 104, and 1.2 103 M, respectively. Relative yield (%) (yield
with added protein/yield with no protein) 100. Where not shown, the S.D.
value is smaller than the symbol.
FIGURE 8. Spectrophotometric titration of ibuprofen binding to HSA-
heme-Fe(III), at pH 7.2 and 22.0 °C. The HSA-heme-Fe(III) concentration
was 1.0 105 M. The continuous linewas calculated according to Equation 8
with L  7.7  104 M. Where not shown, the S.D. value is smaller than the
symbol.
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is in close structural and functional contact with Sudlow’s
site I (i.e. the warfarin binding site), which is allosterically
linked to the heme binding cleft (i.e. FA1) (12, 37). However,
since the dissociation equilibrium constant for ibuprofen
binding to the FA6 site has been reported to fall in the 4.0
107 to 1.3  105 M range (depending on the absence and
presence of allosteric effector(s)) (55), we can also rule out
that the effect of ibuprofen on peroxynitrite isomerization is
related to drug binding to the FA6 site. Indeed, the average
value of the dissociation equilibrium constant for ibuprofen
binding to HSA-heme-Fe(III) here determined (L) from the
dependence of either kon or the relative yield of nitro-L-tyro-
sine or spectrophotometric changes in the Soret band on the
ibuprofen concentration is at least 50-fold higher (8.8 
104 M) (Figs. 6–8).
As a whole, FA2, the only ligand binding site that provides
contacts with different HSA subdomains (being located at
the interface between subdomains IIA and IIB), could repre-
sent the ibuprofen secondary cleft functionally linked to the
heme-Fe(III) atom reactivity (37). Thus, the average value of
L (8.8  104 M) here determined (Figs. 6–8) could reflect
ibuprofen binding to the FA2 site of HSA-heme-Fe(III).
Noticeably, this L value is grossly similar to that obtained
from the ibuprofen-dependent resonance Raman spectro-
scopic changes of HSA-heme-Fe(III), reflecting hexacoordi-
nation of the heme-Fe(III) atom (L  4.0  104 M) (38).
Peroxynitrite isomerization by heme-Fe(III) proteins (e.g.
HSA-heme-Fe(III)) could represent a physiological detoxifica-
tion mechanism, protecting cells from reactive nitrogen and
oxygen species (78). Note that values of kon for peroxynitrite
isomerization by HSA-heme-Fe(III) are higher by about 1
order of magnitude than those reported for ferric horse heart
Mb, sperm whale Mb, human Hb, and heme-model com-
pounds (67, 70, 82, 83) (supplemental Table S2). Moreover,
peroxynitrite isomerization by HSA-heme-Fe(III) (supple-
mental Table S2) is faster than peroxynitrite scavenging by
ferrous nitrosylated heme proteins, which appears to be
strongly limited by (i) the dissociation of the transient heme-
Fe(III)-NO and (ii) the reduction of the final heme-Fe(III)
species to the heme-Fe(II) derivative (50). Remarkably, per-
oxynitrite isomerization by heme-Fe(III) proteins (e.g. HSA-
heme-Fe(III)) does not require any redox cycle.
Due to the relevant physiological role of HSA in human
plasma, several in vivo implications can be argued from the
present results. Indeed, peroxynitrite isomerization by HSA-
heme-Fe(III) could occur only in patients affectedwith a variety
of severe hematologic diseases characterized by excessive intra-
vascular hemolysis. Under these pathological conditions, the
HSA-heme-Fe(III) plasmatic level increases from the physio-
logical concentration (
1 106 M) to
4 105 M (59, 84),
HSA acting as the main heme-Fe(III) plasma depot (84, 85). To
mimic as much as possible this condition, the HSA-heme-
Fe(III) concentration here used ranged from 5.0  106 to
5.0  105 M. The high heme plasma concentration is invari-
ably associated with a reduction of hemopexin in patients
affected by excessive intravascular hemolysis (59). Note that
upon increasing heme plasma level, hemopexin, whose plasma
concentration (
1.5  105 M) (84, 85) is about 2 orders of
magnitude lower than that of HSA (7.5  104 M) (3), under-
goes heme saturation, highlighting the role of HSA as a heme
scavenger (84, 85).
Although the in vivo concentration of peroxynitrite is openly
debated, the level of peroxynitrite in the reperfused ischemic
heart has been reported to be much higher than micromolar
concentration, at least over brief period of time (86, 87), over-
lapping with the lowest peroxynitrite concentration here used
(2.5 105 M).
Finally, considering the plasma level of ibuprofen (
104
to 103 M) (88–90), the drug concentration here used ranged
between 5.0  105 M and 1.0  102 M. Accounting for the
average L value (
8.8  104 M) here determined and the
plasma level of ibuprofen, the molar fraction of the drug-
bound HSA-heme-Fe(III) could range between 10 and 50%.
CONCLUSIONS
Data here reported highlight the role of drugs in modulating
HSA functions. This is relevant for the potential role played by
HSA-heme in the detoxification process, also taking into
account that the HSA-heme-Fe(III) plasmatic concentration
increases significantly under pathological conditions (11, 13,
52, 59, 84). Therefore, the higherHSA-heme concentration and
the higher efficiency of peroxynitrite isomerization altogether
contribute to identify HSA-heme as a major detoxification ele-
ment in the bloodstream. This aspect acquires an even higher
value in consideration of the protective role, played by the per-
oxynitrite isomerization, on the nitration of aromatic residues
(such as tyrosine), which represent a relevant post-translational
proteinmodification process (91). Last, HSA, not only acting as
a heme carrier but also displaying transient heme-based prop-
erties, represents a case for “chronosteric effects” (52), which
opens the scenario toward the possibility of a time- and
metabolite-dependent multiplicity of roles for HSA.
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VOLUME 282 (2007) PAGES 4288–4300
DOI 10.1074/jbc.A111.608307
Activation of JNK-dependent pathway is required for
HIV Viral Protein R-induced apoptosis in human
monocytic cells. INVOLVEMENT OF ANTIAPOPTOTIC BCL2
AND c-IAP1 GENES.
Sasmita Mishra, Jyoti P. Mishra, and Ashok Kumar
PAGE 4293:
Fig. 3A (upper rightpanel) showsanalterationof a lane (10MPD98059)
that was not detected at the time of manuscript submission and that is
contrary to the Journal of Biological Chemistry guidelines. Herein, we pro-
vide an alternative figure that shows that the ERK inhibitor PD98059 inhib-
ited Vpr-(52–96)-induced ERK activation in a dose-dependent manner.
THP-1 cellswere treatedwith the indicated concentrations of PD98059 for
4 h, followed by stimulation with 1.5 M Vpr-(52–96) peptide for another
2 h. The legend of this figure remains unchanged. The data support the
published observations and therefore do not impact the interpretation of
this figure or the central conclusion of this article.
VOLUME 285 (2010) PAGES 21858–21867
DOI 10.1074/jbc.A110.117291
Nucleolar targeting of the chaperone Hsc70 is regulated
by stress, cell signaling, and a composite targeting
signal which is controlled by autoinhibition.
Piotr Ban´ski, HichamMahboubi, Mohamed Kodiha, Sanhita Shrivastava,
Cynthia Kanagaratham, and Ursula Stochaj
During the continuation of our work on hsc70 trafficking, we have
noticed that there was an error during the preparation of midiprep
plasmid DNA for two constructs that were described in this work. The
error reported by us does not alter the validity of the raw data. The
following two constructs were affected by the error: GFP-hsc70(225–
262) and GFP-hsc70(245–287). These two plasmid DNAs have been
inverted in our article. Following the detection of the error, we have
verified the correctness of all other constructs encoding wild-type or
mutant fragments of domain IIB of hsc70. This error affects the presen-
tation of results shown in Figs. 2B and 3 (A andC) and the interpretation
depicted in Fig. 6A. Thus, the correct interpretation of our data is that
segment 245–287 locates constitutively in the nucleolus under non-
stress and stress conditions. Fragment 225–262 displays weak stress-
induced nucleolar accumulation. Thismakes residues 225–244 the neg-
ative regulator of hsc70 nucleolar accumulation.
VOLUME 284 (2009) PAGES 6079–6092
DOI 10.1074/jbc.A111.806077
Preparation and properties of asymmetric vesicles that
mimic cell membranes. EFFECT UPON LIPID RAFT
FORMATIONAND TRANSMEMBRANEHELIX ORIENTATION.
Hui-Ting Cheng, Megha, and Erwin London
The experiments reported were carried out at 390 mM methyl--
cyclodextrin (MCD; 825 mg 1 ml of water, which gives a volume of
1.6 ml), not as reported at 625 mM MCD (825 mg/ml of solution).
We (MiJin Son and E. L.) have investigated asymmetric vesicle prepara-
tion at the higherMCD concentration and found that 625 mMMCD
could be used to produce asymmetric small unilamellar vesicles. How-
ever, the results were not as reproducible as with the lower MCD
concentration. We recommend the use of 390 mM MCD to prepare
asymmetric small unilamellar vesicles.
VOLUME 284 (2009) PAGES 31006–31017
DOI 10.1074/jbc.A109.010736
Ibuprofen impairs allosterically peroxynitrite
isomerization by ferric human serum heme-albumin.
Paolo Ascenzi, Alessandra di Masi, Massimo Coletta, Chiara Ciaccio, Gabriella
Fanali, Francesco P. Nicoletti, Giulietta Smulevich, and Mauro Fasano
For graphical reasons, kobs (kon 10) [HSA-heme-Fe(III)] k0
and kobsi  (koni  10) [HSA-heme-Fe(III)] k0i . Although the values
of kon and koni are reported correctly in the text and in Tables 1 and 2,
derivation fromdata reported in Figs. 2, 3, and 5 corresponds to kon 10
and koni  10.
VOLUME 285 (2010) PAGES 473–482
DOI 10.1074/jbc.A109.040238
YybT is a signaling protein that contains a cyclic
dinucleotide phosphodiesterase domain and a GGDEF
domain with ATPase activity.
Feng Rao, Rui Yin See, Dongwei Zhang, Delon Chengxu Toh, Qiang Ji,
and Zhao-Xun Liang
PAGE 473:
The first sentence in the Abstract should read as follows: The cyclic
dinucleotide c-di-AMP synthesized by the diadenylate cyclase domain
was discovered recently as a messenger molecule for signaling DNA
breaks in Bacillus subtilis.
In the Introduction, line 21 in the right-hand column should read as
follows: This group of proteins (COG3887), as represented by the
B. subtilis protein YybT, contains two N-terminal transmembrane hel-
ices, a region that shares minimum sequence homology with some Per-
Arnt-Sim (PAS) domains, a highly modified GGDEF domain, and a
DHH/DHHA1 domain (see Fig. 1).
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